<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="14311"><DrugName>GCS-100 (iv, end stage renal disease/renal transplantation/cancer), La Jolla Pharmaceutical</DrugName><DrugSynonyms><Name><Value>GBC-590</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GCS-100 (iv)</Value></Name><Name><Value>GCS-100LE</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NCCG, IGG</Value></Name><Name><Value>NCCG, SafeScience</Value></Name><Name><Value>GCS-100 (intravenous, cancer), GlycoGenesys</Value></Name><Name><Value>GCS-100 (intravenous, cancer), Prospect Therapeutics</Value></Name><Name><Value>GCS-100 (iv, end stage renal disease/renal transplantation/cancer), La Jolla Pharmaceutical</Value></Name><Name><Value>GCS-100 (intravenous, cancer), Solana Therapeutics</Value></Name><Name><Value>GCS-100</Value></Name></DrugSynonyms><CompanyOriginator id="22525">GlycoGenesys Inc</CompanyOriginator><CompaniesSecondary><Company id="1034100">Prospect Therapeutics Inc</Company><Company id="1067663">Solana Therapeutics Inc</Company><Company id="15873">Elan Corp plc</Company><Company id="17748">La Jolla Pharmaceutical Co</Company><Company id="22525">GlycoGenesys Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14311" type="Drug"><TargetEntity id="229767" type="siDrug">GCS-100LE</TargetEntity></SourceEntity><SourceEntity id="1034100" type="Company"><TargetEntity id="5021244391" type="organizationId">Prospect Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="1067663" type="Company"><TargetEntity id="5037276872" type="organizationId">Solana Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="15873" type="Company"><TargetEntity id="4295874887" type="organizationId">Perrigo Corporation DAC</TargetEntity></SourceEntity><SourceEntity id="17748" type="Company"><TargetEntity id="4295906958" type="organizationId">La Jolla Pharmaceutical Co</TargetEntity></SourceEntity><SourceEntity id="22525" type="Company"><TargetEntity id="4295914860" type="organizationId">Glycogenesys Inc</TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"></TargetEntity><TargetEntity id="690" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="201" type="ciIndication"><TargetEntity id="10024670" type="MEDDRA"></TargetEntity><TargetEntity id="D008107" type="MeSH"></TargetEntity><TargetEntity id="-35813413" type="omicsDisease"></TargetEntity><TargetEntity id="415" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2989" type="ciIndication"><TargetEntity id="T86.11" type="ICD10"></TargetEntity><TargetEntity id="10023439" type="MEDDRA"></TargetEntity><TargetEntity id="1136" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3251" type="ciIndication"><TargetEntity id="N18.6" type="ICD10"></TargetEntity><TargetEntity id="D007676" type="MeSH"></TargetEntity><TargetEntity id="1604" type="siCondition"></TargetEntity><TargetEntity id="1890" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"></TargetEntity><TargetEntity id="D015179" type="MeSH"></TargetEntity><TargetEntity id="-1280257855" type="omicsDisease"></TargetEntity><TargetEntity id="594" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="650" type="Action"><TargetEntity id="1467" type="Mechanism">Drugs Targeting Adhesion Molecules</TargetEntity><TargetEntity id="872" type="Mechanism">Cell Adhesion Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="9979" type="Action"><TargetEntity id="2635" type="Mechanism">Galectin 3 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="961" type="Action"><TargetEntity id="3283" type="Mechanism">Angiogenic Factor Modulators</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="PTGT-02328" type="ciTarget"><TargetEntity id="165743302239583" type="siTarget">Galectin-3</TargetEntity><TargetEntity id="-1006487068" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="201">Liver disease</Indication><Indication id="205">Melanoma</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="276">Prostate tumor</Indication><Indication id="2989">Kidney transplant rejection</Indication><Indication id="3251">End stage renal disease</Indication><Indication id="651">Cancer</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="9979">Galectin-3 inhibitor</Action><Action id="650">Cell adhesion molecule inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1589">Apoptosis stimulator</Action><Action id="695">Metastasis inhibitor</Action><Action id="7293">Synergist</Action><Action id="961">Angiogenesis modulator</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="159">Oligosaccharide</Technology></Technologies><LastModificationDate>2017-11-24T16:24:49.000Z</LastModificationDate><ChangeDateLast>2017-01-19T00:00:00.000Z</ChangeDateLast><AddedDate>1997-01-14T14:37:29.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17748" linkType="Company"&gt;La Jolla Pharmaceutical&lt;/ulink&gt;, under license from &lt;ulink linkID="1067663" linkType="Company"&gt;Solana Therapeutics&lt;/ulink&gt; (presumably acquired  through auction from &lt;ulink linkID="1034100" linkType="Company"&gt;Prospect Therapeutics&lt;/ulink&gt;' creditors), was developing an iv formulation of  GCS-100, a modified pectin, an anti-fibrotic  iv galectin-3  inhibitor, for the potential treatment of   chronic kidney disease and is investigating the drug for the potential treatment of cancer with renal insufficiency and renal transplantation  rejection,  and liver disease and for the potential prevention of  chemotherapy toxicity   [&lt;ulink linkID="229641" linkType="reference"&gt;229641&lt;/ulink&gt;], [&lt;ulink linkID="414205" linkType="reference"&gt;414205&lt;/ulink&gt;], [&lt;ulink linkID="821842" linkType="Reference"&gt;821842&lt;/ulink&gt;], [&lt;ulink linkID="1256452" linkType="Reference"&gt;1256452&lt;/ulink&gt;], [&lt;ulink linkID="1280342" linkType="Reference"&gt;1280342&lt;/ulink&gt;], [&lt;ulink linkID="1306570" linkType="Reference"&gt;1306570&lt;/ulink&gt;], [&lt;ulink linkID="1350887" linkType="Reference"&gt;1350887&lt;/ulink&gt;]. In June 2013, a phase II trial for chronic kidney disease was initiated in the US [&lt;ulink linkID="1415877" linkType="Reference"&gt;1415877&lt;/ulink&gt;]; in March 2014, positive topline results were reported [&lt;ulink linkID="1533412" linkType="Reference"&gt;1533412&lt;/ulink&gt;]; in January 2014, a phase II extension study was initiated in CKD patients [&lt;ulink linkID="1515825" linkType="Reference"&gt;1515825&lt;/ulink&gt;]. In March 2015, a phase IIb trial was initiated in CKD patients [&lt;ulink linkID="1643007" linkType="Reference"&gt;1643007&lt;/ulink&gt;]. In April 2012,  the company was also planning to initiate a melanoma trial [&lt;ulink linkID="1280342" linkType="Reference"&gt;1280342&lt;/ulink&gt;]; in July 2012, the company planned to initiate trials for melanoma, renal toxicity and renal transplatation   rejection,  after completing respective preclinical testing [&lt;ulink linkID="1306570" linkType="Reference"&gt;1306570&lt;/ulink&gt;]. In December 2012,  La Jolla planned to file an IND with the FDA for the treatment of liver disease [&lt;ulink linkID="1350887" linkType="Reference"&gt;1350887&lt;/ulink&gt;].  However, in May 2015, the program was discontinued due to pipeline reprioritization [&lt;ulink linkID="1657884" linkType="Reference"&gt;1657884&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Prospect Therapeutics (formerly Marlborough Research and Development), following the liquidation of &lt;ulink linkID="22525" linkType="Company"&gt;GlycoGenesys&lt;/ulink&gt; (formerly SafeScience),  was developing GCS-100 (formerly GBC-590),  an iv carbohydrate-based lectin inhibitor, for the potential treatment of   cancers  [&lt;ulink linkID="229641" linkType="reference"&gt;229641&lt;/ulink&gt;], [&lt;ulink linkID="414205" linkType="reference"&gt;414205&lt;/ulink&gt;], [&lt;ulink linkID="821842" linkType="Reference"&gt;821842&lt;/ulink&gt;].  In June 2008, Prospect reported positive results from a phase II CLL trial. At that time, the drug was reported to be in phase I for multiple myeloma (MM) and the  company  was planning a CLL trial to evaluate the drug in combination with chemotherapy and a B-cell lymphoma trial in  2008 [&lt;ulink linkID="913322" linkType="Reference"&gt;913322&lt;/ulink&gt;]. By  January 2008, Prospect planned to begin a phase I/II MM trial in February 2008 [&lt;ulink linkID="913764" linkType="Reference"&gt;913764&lt;/ulink&gt;]. However, in May 2009, the company assigned all of its assests to creditors to be auctioned off at a later date and it was presumed that  all of Prospect's drug development had been discontinued  [&lt;ulink linkID="1009210" linkType="Reference"&gt;1009210&lt;/ulink&gt;], [&lt;ulink linkID="1011278" linkType="Reference"&gt;1011278&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;SafeScience began phase I/II  trials in prostate cancer in June 1999 [&lt;ulink linkID="329224" linkType="reference"&gt;329224&lt;/ulink&gt;]. Phase II  trials in colorectal carcinoma were initiated in June 2000 and phase II  trials for pancreatic carcinoma had been completed by April 2002 [&lt;ulink linkID="378951" linkType="reference"&gt;378951&lt;/ulink&gt;], [&lt;ulink linkID="369718" linkType="reference"&gt;369718&lt;/ulink&gt;], [&lt;ulink linkID="416607" linkType="reference"&gt;416607&lt;/ulink&gt;], [&lt;ulink linkID="446388" linkType="reference"&gt;446388&lt;/ulink&gt;].  However, following the liquidation of GlycoGenesys in June 2006, it is presumed that development for these indications had been discontinued [&lt;ulink linkID="821842" linkType="Reference"&gt;821842&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Originally GlycoGenesys was collaborating with &lt;ulink linkID="15873" linkType="Company"&gt;Elan&lt;/ulink&gt; on the development of the compound; but in July 2002, Elan began a restructuring plan and was no longer focusing in oncology research [&lt;ulink linkID="459736" linkType="reference"&gt;459736&lt;/ulink&gt;]. By September 2002, Elan had discontinued its oncology programs and was seeking to divest its oncology assets [&lt;ulink linkID="464870" linkType="reference"&gt;464870&lt;/ulink&gt;]. In December 2002, GlycoGenesys acquired all of Elan's interest in their oncology joint venture, SafeScience Newco Ltd, in exchange for a royalty interest on certain future revenues related to GCS-100 [&lt;ulink linkID="474568" linkType="reference"&gt;474568&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;GlycoGenesys was also developing GCS-100LE, an ethanol-free formulation of GCS-100, for the potential treatment of cancer, and investigating it for the potential treatment of diseases related to angiogenesis [&lt;ulink linkID="616694" linkType="Reference"&gt;616694&lt;/ulink&gt;]. Phase I trials  in solid tumors were initiated in May 2004 [&lt;ulink linkID="538126" linkType="reference"&gt;538126&lt;/ulink&gt;]. A phase I/II multiple myeloma trial of GCS-100LE began in April 2005 [&lt;ulink linkID="593503" linkType="Reference"&gt;593503&lt;/ulink&gt;]. In January 2005, the company was seeking to outlicense  rights to the drug to  a strategic partner in order to   progress trials planned for that year [&lt;ulink linkID="581652" linkType="Reference"&gt;581652&lt;/ulink&gt;]. By October 2005, several companies had expressed interest in licensing the drug but were waiting for interim MM trial results in April 2006 before committing to licensing deals [&lt;ulink linkID="630225" linkType="Reference"&gt;630225&lt;/ulink&gt;]; however, following the liquidation of GlycoGenesys in June 2006, it is presumed that development of GCS-100LE had been discontinued [&lt;ulink linkID="821842" linkType="Reference"&gt;821842&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;GlycoGenesys was also investigating an &lt;ulink linkID="53698" linkType="Drug"&gt;oral formulation of GCS-100&lt;/ulink&gt;, for the treatment of cancer.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Chronic Kidney Disease&lt;/subtitle&gt;In November 2014, the company planned to initiate a multicenter, randomized, placebo-controlled, phase IIb trial in CKD In the first quarter of 2015 [&lt;ulink linkID="1611705" linkType="Reference"&gt;1611705&lt;/ulink&gt;]. In December 2014, the double-blind, safety/efficacy  trial (&lt;ulink linkID="217930" linkType="Protocol"&gt;NCT02312050&lt;/ulink&gt;;  LJ100-CKD04) was expected to be completed in December 2016 in patients (expected n = 375), with CKD in the US  [&lt;ulink linkID="1643141" linkType="Reference"&gt;1643141&lt;/ulink&gt;]. In March 2015, the trial was initiated [&lt;ulink linkID="1643007" linkType="Reference"&gt;1643007&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, the company initiated a randomized, phase II extension study (GCS-100-CS-4003) in CKD patients (expected n = 115) who completed the 12-week GCS-100-CS-4002 study to evaluate the long-term safety, tolerability and efficacy of  drug administered intravenously once-weekly for up to 8 consecutive weeks with a 4 week follow-up period and then at least once a month for a total of  one year. At that time, initial data were expected in March 2014 [&lt;ulink linkID="1515825" linkType="Reference"&gt;1515825&lt;/ulink&gt;]. In June 2014, enrollment of patients (n = 93) was completed across 5 sites and at that time, initial data were expected later that year [&lt;ulink linkID="1566007" linkType="Reference"&gt;1566007&lt;/ulink&gt;]. In November 2014, clinical data were presented at the ASN Kidney Week 2014 in Philadelphia, PA.										The results of phase II extension study were consistent with phase II study when compared with the parallel randomized group receiving GCS-100 (30 mg/m2) and response to placebo in the phase II study. GCS-100 (1.5 mg/m2) was safe and well tolerated [&lt;ulink linkID="1610259" linkType="Reference"&gt;1610259&lt;/ulink&gt;],  [&lt;ulink linkID="1611701" linkType="Reference"&gt;1611701&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In May 2013, the company was planning to initiate a randomized phase IIa trial in adult patients   (expected n = 117) with stage IIIb or IV CKD, in early June 2013 [&lt;ulink linkID="1430232" linkType="Reference"&gt;1430232&lt;/ulink&gt;]; in June 2013, the study was initiated [&lt;ulink linkID="1443742" linkType="Reference"&gt;1443742&lt;/ulink&gt;],  [&lt;ulink linkID="1415877" linkType="Reference"&gt;1415877&lt;/ulink&gt;]. In July 2013, the first patient was dosed in the single-blind, multicenter, placebo-controlled study, conducted in the US (&lt;ulink linkID="126495" linkType="Protocol"&gt;NCT01843790&lt;/ulink&gt;; GCS-100-CS-4002). At that time, the study was expected to complete in October 2013 [&lt;ulink linkID="1449620" linkType="Reference"&gt;1449620&lt;/ulink&gt;],   [&lt;ulink linkID="1449528" linkType="Reference"&gt;1449528&lt;/ulink&gt;], [&lt;ulink linkID="1566007" linkType="Reference"&gt;1566007&lt;/ulink&gt;]. In December 2013, patient enrollment was completed. A total of 121 patients were enrolled and were randomly assigned 1:1:1 to treatment with placebo, 1.5 or 30 mg/m2 of GCS-100. Additionally, randomization was stratified by baseline renal function, defined by eGFR values of 15-29 and 30-44 mL/min/1.73m2. At that time, primary endpoint data were expected in April 2014 and the full data package was expected before the end of the second quarter 2014 [&lt;ulink linkID="1509291" linkType="Reference"&gt;1509291&lt;/ulink&gt;]. In February 2014, primary efficacy endpoint data were expected to be reported in March 2014 [&lt;ulink linkID="1527317" linkType="Reference"&gt;1527317&lt;/ulink&gt;]. Later that month, final dosing of the study was completed and patients were followed-up for 4 weeks after 8 weeks of treatment. The final data were collected to evaluate the primary efficacy endpoint. Out of 121 subjects, 117 subjects had completed the study [&lt;ulink linkID="1527696" linkType="Reference"&gt;1527696&lt;/ulink&gt;]. In March 2014, positive topline results were reported that GCS-100 was well-tolerated and met its primary endpoint of statistically significant increase in estimated glomerular filtration rate compared to placebo at 1.5 mg/m2 dose level. The drug also met its secondary endpoint of statistically significant reduction in circulating levels of galectin-3 along with improvement in potassium, uric acid and blood urea nitrogen at 1.5 mg/m2 dose level [&lt;ulink linkID="1533412" linkType="Reference"&gt;1533412&lt;/ulink&gt;]. In November 2014, data were presented at at the American Society of Nephrology’s (ASN) Kidney Week Annual Meeting. Data demonstrated that  the drug met its primary efficacy endpoint of a statistically significant improvement in kidney function [&lt;ulink linkID="1611705" linkType="Reference"&gt;1611705&lt;/ulink&gt;]. Similar clinical data were presented at the same conference [&lt;ulink linkID="1610259" linkType="Reference"&gt;1610259&lt;/ulink&gt;],  [&lt;ulink linkID="1611701" linkType="Reference"&gt;1611701&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;GCS-100Melanoma&lt;/subtitle&gt;In April 2012, the company was planning to initiate a melanoma trial [&lt;ulink linkID="1280342" linkType="Reference"&gt;1280342&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cancer with renal insufficiency&lt;/subtitle&gt;In April 2012, the company planned to initiate clinical trials in cancer patients with renal insufficiency in 2012 [&lt;ulink linkID="1280342" linkType="Reference"&gt;1280342&lt;/ulink&gt;]. By July 2012, the company planned  to initiate a phase I/II study (GCS-100-CS-1001) to evalute the effect of weekly doses of GCS-100  in patients with advanced cancer who have renal insufficiency  [&lt;ulink linkID="1306570" linkType="Reference"&gt;1306570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Chronic Lymphocytic Leukemia&lt;/subtitle&gt;In June 2008,  Prospect reported preliminary data from an ongoing phase II trial. Results from six evaluable patients showed that GCS-100 activated caspases -8 and -9 in CLL cells, inducing apoptosis. Two patients had a 76 and 42% significant reduction in leukocyte counts from baseline and had reduced lymph node size. The drug was generally well tolerated, with rash the most common adverse event. At that time, Prospect was planning another trial which would evaluate GCS-100 in combination with chemotherapy [&lt;ulink linkID="913322" linkType="Reference"&gt;913322&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2007, a non-randomized, open-label, single group assignment, phase I trial (&lt;ulink linkID="37298" linkType="Protocol"&gt;NCT00514696&lt;/ulink&gt;; PR-CS008-03) was initiated in subjects (expected n = 12) with CLL in the US.  The subjects were to receive up to 15 cycles of GCS-100 for a total treatment period of 21 days. The primary endpoint was to evaluate the effect of GCS-100 on markers of apoptosis. At that time, the trial was scheduled to complete in February 2008, and in August 2007, the trial was still recruiting [&lt;ulink linkID="821878" linkType="Reference"&gt;821878&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Multiple myeloma&lt;/subtitle&gt;By January 2008, Prospect planned to begin a phase I/II, safety and efficacy trial (&lt;ulink linkID="25430" linkType="Protocol"&gt;NCT00609817&lt;/ulink&gt;; PR-CS009) in February 2008. The open-label, non-randomized  trial would enroll 40 patients with MM to receive up to twelve iv infusions of GCS-100 at 160 mg/m2 in 21-day cycles. The primary endpoint would be to identify the maximum tolerated dose, while secondary endpoints would compare safety of the drug when administered in combination with &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt;. The trial was expected to complete in September 2009 [&lt;ulink linkID="913764" linkType="Reference"&gt;913764&lt;/ulink&gt;].  In June 2008, the company reported that the drug was in a phase I   MM trial  conducted by the Dana Faber Center  which was presumed to be part of this trial   [&lt;ulink linkID="913322" linkType="Reference"&gt;913322&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;A phase II trial of GCS-100 involving patients with colorectal carcinoma was initiated in June 2000 [&lt;ulink linkID="369718" linkType="reference"&gt;369718&lt;/ulink&gt;]. In September 2000, enrollment for this trial was complete [&lt;ulink linkID="383100" linkType="reference"&gt;383100&lt;/ulink&gt;]. In March 2001, preliminary results from the phase IIa trial, showing that GCS-100 demonstrated positive clinical activity in colorectal cancer patients, were reported. Although a complete analysis of the data was still ongoing, the company planned to conduct an expanded phase IIb dose-escalation trial. In the phase IIa trial, GCS-100 was administered at low dosage to 23 patients who had late-stage cancer with either no response to, or suffered a relapse after, prior chemotherapy treatment. Five patients showed tumor stabilization for periods from 2 months up to 6 months before disease state progression was observed, with one patient showing a period of tumor shrinkage [&lt;ulink linkID="402884" linkType="reference"&gt;402884&lt;/ulink&gt;]. In May 2001, further phase II results were presented at the 37th ASCO meeting in San Francisco, CA. No DLT had been observed at doses up to and including 20 mg/m2, and additional dose escalation studies were being planned at this time [&lt;ulink linkID="410523" linkType="reference"&gt;410523&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I trial at the &lt;ulink linkID="20658" linkType="Company"&gt;University of Pennsylvania&lt;/ulink&gt;, completed in July 1999, GCS-100 was shown to be well tolerated by all patients with colorectal cancer; there was also preliminary evidence of biological activity of GCS-100 in terminal colorectal cancer refractory to all other standard treatments [&lt;ulink linkID="333926" linkType="reference"&gt;333926&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pancreatic carcinoma&lt;/subtitle&gt;In October 2002, results from a phase IIa trial in 20 patients with refractory or relapsed pancreatic adenocarcinoma treated with twice-weekly GCS-100 at 20 mg/m2 were announced. Prior to the trial, all 20 patients had failed or were refractory to either &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; or other standard treatments or both. Results were evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) and WHO tumor progression measurement standards. Seven (35%) patients experienced stable disease from 0.36 to 13.6 months measured by RECIST and two of these seven patients experienced periods of tumor shrinkage. Three (15%) patients achieved stable disease for periods ranging from 3 to 13.6 months when applying WHO criteria. GCS-100 was well tolerated with no dose limiting toxicities or serious adverse events [&lt;ulink linkID="468512" linkType="reference"&gt;468512&lt;/ulink&gt;]. In June 2003, clinical data on GCS-100 were presented at the BIO 2003 meeting in Washington, DC. GlycoGenesys reported that GCS-100 did not cause observable adverse side effect and effected tumor shrinkage at an optimal dose of 150mg/m2  [&lt;ulink linkID="494989" linkType="reference"&gt;494989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2001, phase IIa trials in pancreatic cancer patients were ongoing  [&lt;ulink linkID="404202" linkType="reference"&gt;404202&lt;/ulink&gt;]. In May 2001, results were presented at the 37th ASCO meeting in San Francisco, CA. Again, 20 mg/m2 iv twice weekly was well tolerated, and one patient of 13 achieved stable disease [&lt;ulink linkID="410573" linkType="reference"&gt;410573&lt;/ulink&gt;]. Enrollment was completed in July 2001, with 20 late-stage pancreatic cancer patients taking part [&lt;ulink linkID="416607" linkType="reference"&gt;416607&lt;/ulink&gt;]. In April 2002, the phase IIa trial was completed and the results were being prepared for publication [&lt;ulink linkID="446388" linkType="reference"&gt;446388&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2000, SafeScience received approval for a phase II, open-label, safety, efficacy and pharmacokinetic study of GCS-100 in patients with refractory or relapsing carcinoma of the pancreas, who had failed one prior regime of chemotherapy. The trial commenced later that month [&lt;ulink linkID="366944" linkType="reference"&gt;366944&lt;/ulink&gt;]. Also in April 2000, SafeScience initiated a phase II trial of GCS-100 in patients with pancreatic carcinoma [&lt;ulink linkID="362595" linkType="reference"&gt;362595&lt;/ulink&gt;], [&lt;ulink linkID="363609" linkType="reference"&gt;363609&lt;/ulink&gt;]. In May 2000, SafeScience received approval for phase II studies of GCS-100 for the treatment of pancreatic cancer from the &lt;ulink linkID="20669" linkType="Company"&gt;University of Rochester&lt;/ulink&gt; [&lt;ulink linkID="365192" linkType="reference"&gt;365192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results of preclinical studies presented at the Glycocompounds '98 Conference in November 1998, showed that GCS-100 produced a significant response in the PANC-1 pancreatic tumor cell model in mice. In the group treated with GCS-100, 44% showed a significant response, with tumor stabilization in 11% and eradication of the tumor in 33% [&lt;ulink linkID="303779" linkType="reference"&gt;303779&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In April 2000, SafeScience planned to initiate phase II trials in patients with cancer of the prostate later in 2000 [&lt;ulink linkID="362595" linkType="reference"&gt;362595&lt;/ulink&gt;], [&lt;ulink linkID="363609" linkType="reference"&gt;363609&lt;/ulink&gt;], although by August 2000, phase II trials for prostate cancer weren't expected until the first quarter of 2001 [&lt;ulink linkID="378951" linkType="reference"&gt;378951&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results of a phase I/II trial completed by June 1999, showed that GCS-100 was well tolerated and effective in reducing or stabilizing prostate specific antigens (PSA) levels in 18 out of 22 relapsing prostate cancer patients resistant to standard therapy. No dose limiting toxicities were observed for hematological, renal, hepatic or other end organ functions. Based on these results the company planned to commence phase II studies [&lt;ulink linkID="329224" linkType="reference"&gt;329224&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 1999, 15 prostate cancer patients had taken part in a phase I trial evaluating a dose range from 1.9 to 20.0 mg/m2; although the toxicity profile was satisfactory, no PSA responses were observed [&lt;ulink linkID="327859" linkType="reference"&gt;327859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;GCS-100LE&lt;/subtitle&gt;&lt;subtitle&gt;Solid tumor&lt;/subtitle&gt;In May 2004, GlycoGenesys initiated a phase I trial of GCS-100LE, to evaluate it in up to 30 patients with multiple solid tumor indications. Three to six patients per dose level were to be enrolled until the maximum tolerated dose was reached. Each treatment cycle would consist of five daily infusions of GCS-100LE followed by two weeks off treatment. Cycles would be repeated until disease progression was documented or withdrawal from the trial due to an adverse event [&lt;ulink linkID="538126" linkType="reference"&gt;538126&lt;/ulink&gt;]. In August 2005, the trial was ongoing, and phase III trials were planned for the fourth quarter of 2007 [&lt;ulink linkID="616694" linkType="Reference"&gt;616694&lt;/ulink&gt;]. In September 2005, GlycoGenesys reported  preliminary results showing that GCS-100 was well tolerated, had low toxicity and could stabilize tumor growth. Of the 14 patients for whom response data were available, 11 experienced periods of stable disease ranging from 1.5 to over 8 months. Three of these had not responded to any previous therapies. The trial achieved its primary endpoint of establishing the maximum tolerated dose of the iv carbohydrate-based lectin inhibitor for 5 consecutive days followed by 2 weeks off. The dose-limiting toxicity was a rash, manageable with steroid therapy. At that time, the study continued to enroll patients [&lt;ulink linkID="622142" linkType="Reference"&gt;622142&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Multiple myeloma&lt;/subtitle&gt;In January 2005, GlycoGenesis was planning to launch a first MM clinical trial in the first quarter of the year. This study would assess the drug's safety and determine dosages; secondary objectives would be to determine efficacy, both as a monotherapy and in combination with dexamethosone. A second trial was scheduled to begin later that year and the company hoped to file an NDA for this indication in 2007 [&lt;ulink linkID="581652" linkType="Reference"&gt;581652&lt;/ulink&gt;]. In April 2005, the dose-escalation trial was initiated. Patients would receive two monotherapy doses of GCS-100LE per week for 2 weeks, followed by 1 week off. If patients progressed after 2 cycles or remained stable after 4 cycles, dexamethasone might be added to their treatment. Patients showing a partial or complete response to either monotherapy or combination therapy would continue on such treatment. The primary objective of the study was to assess safety, and the secondary objectives for the drug included efficacy as a monotherapy and in combination with dexamethasone, and pharmacokinetics alone and with dexamethasone [&lt;ulink linkID="593503" linkType="Reference"&gt;593503&lt;/ulink&gt;]. In August 2005, the trial was expected to be completed in the third quarter of 2006 [&lt;ulink linkID="616694" linkType="Reference"&gt;616694&lt;/ulink&gt;]. By October 2005, interim results were expected to be available in April 2006 [&lt;ulink linkID="630225" linkType="Reference"&gt;630225&lt;/ulink&gt;]. In November 2005, the company added an additional US clinical site to the trial [&lt;ulink linkID="635641" linkType="Reference"&gt;635641&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Liver  disease&lt;/subtitle&gt;In December 2012, the company planned to file an IND with the FDA for the treatment of liver disease [&lt;ulink linkID="1350887" linkType="Reference"&gt;1350887&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous clinical data&lt;/subtitle&gt;By January 2005, GlycoGenesis had begun enrolling patients at the fifth of six dose levels in a dose escalation solid tumor trial. Two additional site had also been enrolled in the trial [&lt;ulink linkID="581652" linkType="Reference"&gt;581652&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, GlycoGenesys presented results from a phase I trial in late-stage cancer patients at the Rodman Renshaw Techvest conference in Boston, MA. In the open-label, dose-escalating trial, patients received GCS-100 of either 30, 42.5, 60 or 80 mg/m2 twice-weekly iv for up to 6 months. Of the 12 patients enrolled, 2 had stable disease for 3 months and 3 had stable disease for over 5 months. One patient continued to take GCS-100 for over 18 months and had a partial response [&lt;ulink linkID="510060" linkType="reference"&gt;510060&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2003, GlycoGenesys planned to start three phase I dose escalation trials with an ethanol-free formulation of GCS-100. The first, planned to begin in early 2004, would use GCS-100 as a monotherapy and enroll up to 30 patients, and the other two trials would evaluate GCS-100 in combination with a different standard chemotherapeutic agent. In addition, two phase II trials were planned evaluating GCS-100 as a monotherapy, as well as two additional phase II trials to evaluate a combination of GCS-100 with approved chemotherapeutic agents [&lt;ulink linkID="506063" linkType="reference"&gt;506063&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, clinical data on GCS-100 were presented at the BIO 2003 meeting in Washington, DC. GlycoGenesys found that when GCS-100 was given in combination with Bristol-Myers Squibb's anticancer agent, VP-16, only a quarter of the dose of VP-16 was needed to achieve the same effect. The company also disclosed that, according to its data, GCS-100 effected an inhibition of the VEGF receptor [&lt;ulink linkID="494989" linkType="reference"&gt;494989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, the company initiated a new phase I dose escalation trial with GCS-100. The primary objectives of this study were to investigate the pharmacokinetics and maximum tolerated dose of GCS-100. It was expected that the trial would help to identify an appropriate dose which would be used in subsequent clinical trials to determine the efficacy of GCS-100 [&lt;ulink linkID="446388" linkType="reference"&gt;446388&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2000, the company also planned to initiate phase II trials involving patients with liver cancer later in 2000 [&lt;ulink linkID="362595" linkType="reference"&gt;362595&lt;/ulink&gt;], [&lt;ulink linkID="363609" linkType="reference"&gt;363609&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 1999, SafeScience reported results of its phase I trial for GCS-100 in patients with end-stage cancer refractory to all other standard therapies (disease types included pancreatic, colorectal, lung and esophageal carcinomas and metastatic sarcoma). The compound was well tolerated at all administered dose levels. These data confirmed the safety profile which was first reported from the phase I trial in prostate cancer [&lt;ulink linkID="333926" linkType="reference"&gt;333926&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 1997, GCS-100 entered phase I trials in cancer patients [&lt;ulink linkID="240220" linkType="reference"&gt;240220&lt;/ulink&gt;]. By May 1999, a total of nine patients had been evaluated. The studied dose range varied from 1.9 to 20.0 mg/m2. The therapy was administered as an infusion and although this was a well-tolerated regimen, no anticancer effects were observed [&lt;ulink linkID="327442" linkType="reference"&gt;327442&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2014, preclinical data were presented at the 56th ASH Meeting in San Francisco, CA. In OCI-AML3 cells,  treatment with GCS-100 + ABT-737 combination synergistically induced apoptosis and GCS-100 alone inhibited ERK-activation, suppressed MCL-1 and BCL-2 expression, and altered gene expression  [&lt;ulink linkID="1635318" linkType="Reference"&gt;1635318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, positive data from a mouse study examining the effect of GCS-100 on liver fibrosis were reported. In the 12-week STAM model for Non-alcoholic Steatohepatitis-hepatocellular carcinoma, GCS-100 showed a statistically significant reduction in liver fibrosis, a statistically significant improvement in the Non-Alcoholic Fatty Liver Disease score and a statistically significant improvement in liver function, compared to placebo-treated animals. The drug was well tolerated and  decreased plasma ALT. GCS-100 treated animals showed a  decrease in the hydroxyproline amount [&lt;ulink linkID="1350887" linkType="Reference"&gt;1350887&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, preclinical data were published showing that GCS-100 removed the protective effect of galectin-3 on lymphoma cells, making them more susceptible to chemotherapy agents [&lt;ulink linkID="1332032" linkType="Reference"&gt;1332032&lt;/ulink&gt;], [&lt;ulink linkID="1332220" linkType="Reference"&gt;1332220&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By July 2012, the company planned to initiate preclinical testing of  GCS-100  for renal transplantation rejection    [&lt;ulink linkID="1306570" linkType="Reference"&gt;1306570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2012, the company planned to initiate preclinical testing using GCS-100 in prevention of cisplatin induced renal toxicity    [&lt;ulink linkID="1306570" linkType="Reference"&gt;1306570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2012, the company planned to initiate preclinical testing of GCS-100 in combination  with &lt;ulink linkID="36630" linkType="Drug"&gt;ipilimumab&lt;/ulink&gt; for melanoma  [&lt;ulink linkID="1306570" linkType="Reference"&gt;1306570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, the company planned to evaluate GCS-100 in combination with &lt;ulink linkID="36630" linkType="Drug"&gt;Yervoy&lt;/ulink&gt;  in preclinical  models [&lt;ulink linkID="1280342" linkType="Reference"&gt;1280342&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By July 2010, data from studies in tumor-bearing mice had demonstrated that vaccination with a tumor antigen and injections of GCS-100 led to tumor rejection in half of the mice, whereas all control mice died. In nonvaccinated mice, GCS-100 had no effect by itself. Data from  ex vivo studies had shown that GCS-100 reactivated killer T-cells directed at the cancer that have been silenced by galectin-3 [&lt;ulink linkID="1280478" linkType="Reference"&gt;1280478&lt;/ulink&gt;], [&lt;ulink linkID="1280342" linkType="Reference"&gt;1280342&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, preclinical data on GCS-100 were presented at the  48th ASH meeting in Orlando, which showed that GCS-100 inhibited myeloma cell progression through the G1/S phase of the cell cycle, and induced apoptosis in a dose and time dependent manner [&lt;ulink linkID="750792" linkType="Reference"&gt;750792&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2005, preclinical data were published which showed that GCS-100 decreased galectin-3 expression in multiple myeloma (MM) cells when administered with dexamethasone. The decrease correlated with increased antitumor activity. GCS-100 was also found to selectively induce apoptosis in MM cell lines without killing normal white blood cells; to block the growth of MM cells from patients resistant to &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt;, thalidomide and dexamethasone; and to inhibit the growth of MM cells [&lt;ulink linkID="623615" linkType="Reference"&gt;623615&lt;/ulink&gt;], [&lt;ulink linkID="623620" linkType="Reference"&gt;623620&lt;/ulink&gt;].  Similar data were presented in December 2005, at the 47th ASH meeting in Atlanta, GA [&lt;ulink linkID="640663" linkType="Reference"&gt;640663&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in September 2005, preclinical data presented at the XIth International Workshop on CLL in New York, NY, showed that GCS-100 dose-dependently downregulated AKT1 in lymphoma, myeloma and CLL cell lines [&lt;ulink linkID="623782" linkType="Reference"&gt;623782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2005, information relating to the mechanism of action for GCS-100 was presented at the 9th International Conference on Malignant Lymphoma in Lugano, Switzerland. Research showed that GCS-100 binds to galectin-3 and prevents it from co-locating with Bcl-2 in a variety of lymphoma and solid tumor cell lines causing targeted cell death, which occurs via the caspase-9 mediated pathway. GCS-100 also had the ability to enhance the effect of chemotherapeutic agents, including etoposide [&lt;ulink linkID="607590" linkType="Reference"&gt;607590&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2005, GCS-100LE had been shown to induce cell death in MM cells without significant toxicity against normal white blood cells, directly target MM cells while in the presence of protective bone marrow cells, trigger cell death in MM cells resistant to  dexamethasone, melphalan, doxorubicin, and &lt;ulink linkID="15954" linkType="Drug"&gt;velcade&lt;/ulink&gt;, and have additive and synergistic effects when combined with  dexamethasone and PK11195, respectively [&lt;ulink linkID="593503" linkType="Reference"&gt;593503&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, preclinical data on GCS-100 were presented at the 46th ASH meeting in San Diego, CA. Treatment of MM cell lines with GCS-100 triggered growth arrest and apoptosis, as did treatment of purified patient MM cells, without significant toxicity. The compound also decreased the viability of bortezomib-resistant MM patient cells [&lt;ulink linkID="573764" linkType="Reference"&gt;573764&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Additional preclinical data on GCS-100 in indolent B-cell lymphomas were presented at the 46th ASH meeting. The mechanism of induction of apoptosis by GCS-100 was investigated by testing varying doses in B-cell lymphoma and leukemia cell lines (DoHH2, Ramos, BV173 and K562), primary patient CD19 selected CLL cells and normal B-cells in short term cultures. Chemotherapy post compound was undertaken to investigate enhanced antitumor activity. GCS-100  induced significant apoptosis in the intrinsic mitochondrial and caspase-9 pathway of both malignant cell lines and primary patient CLL cells in vitro, with a minimal effect against normal B-cells. At low dosage GCS-100 enhanced the apoptotic effect of chemotherapy, even in the presence of high levels of anti-apoptotic proteins such as Bcl-2. Gal-3 expression was increased in the malignant cells compared to the normal B-cells [&lt;ulink linkID="574124" linkType="Reference"&gt;574124&lt;/ulink&gt;], [&lt;ulink linkID="575021" linkType="Reference"&gt;575021&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, preclinical data were released at the 39th ASCO meeting in Chicago, IL. GCS-100 was shown to kill both a Bcl-2-expressing, chemotherapy-resistant human lymphoma cell line and a non-Bcl-2-expressing cell line [&lt;ulink linkID="492006" linkType="reference"&gt;492006&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;GCS-100 monotherapy produced a significant tumor response, including complete shrinkage and arrest, in an LNCaP human carcinoma xenograft animal model [&lt;ulink linkID="325264" linkType="reference"&gt;325264&lt;/ulink&gt;], [&lt;ulink linkID="32922" linkType="reference"&gt;32922&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;GCS-100, originally referred to as NCCG (natural complex carbohydrate glycoprotein), is designed to recognize specific lectins which appear only on metastatic cells. The substance acts as a molecular decoy, which attaches to the metastatic cell and prevents cell aggregation. Only single metastatic cells remain in the blood circulation and these individual cells marked with the carbohydrate molecule can then be destroyed by the body's immune system. By August 2000, the company was investigating an oral formulation of the product [&lt;ulink linkID="378951" linkType="reference"&gt;378951&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2006, GlycoGenesys  filed for bankruptcy under Chapter 11, cut over half its workforce and announced the resignation of CEO Bradley Carver [&lt;ulink linkID="648512" linkType="Reference"&gt;648512&lt;/ulink&gt;]. In June 2006 the company went into liquidation and in October 2006,  the liquidation sale of  certain GlycoGenesys assets to Prospect Therapeutics (formerly Marlborough Research and Development Inc) was approved [&lt;ulink linkID="821842" linkType="Reference"&gt;821842&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, GlycoGenesis announced that it was seeking a partner to assist with its development of the drug [&lt;ulink linkID="581652" linkType="Reference"&gt;581652&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2004, GCS-100LE's postulated mechanisms of action included apoptosis induction, angiogenesis modulation and cell adhesion interference [&lt;ulink linkID="575870" linkType="Reference"&gt;575870&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2004, GlycoGenesys was issued US-06680306, covering the use of GCS-100 and other carbohydrates that bind galectins prior to or in combination with chemotherapy or surgery for the treatment of cancer [&lt;ulink linkID="523652" linkType="reference"&gt;523652&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, the company revealed that it would expand the GCS-100 program to indications outside oncology [&lt;ulink linkID="494989" linkType="reference"&gt;494989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2001, Safe Science formed a business venture with Elan Corp to further the development of GCS-100. Under the terms of the agreement, both companies would license proprietary technology to the venture [&lt;ulink linkID="412519" linkType="reference"&gt;412519&lt;/ulink&gt;], [&lt;ulink linkID="414205" linkType="reference"&gt;414205&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2001, SafeScience entered into a research collaboration with MIT over the expanded analysis into the mechanisms of action of GPC-590; further aspects of the collaboration included the identification and analysis of other compounds with promising biochemical and pharmaceutical activity [&lt;ulink linkID="422545" linkType="reference"&gt;422545&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2000, SafeScience was awarded AU-0714164 for modified pectin material. This patent is among a series of patents and patent applications related to the carbohydrate structure and function which is the basis for GCS-100 [&lt;ulink linkID="366944" linkType="reference"&gt;366944&lt;/ulink&gt;]. In January 2001, SafeScience secured an exclusive worldwide license to additional patents (US-05895784 and US-05834442) relating to GBC-950 from &lt;ulink linkID="20702" linkType="Company"&gt;Wayne State University&lt;/ulink&gt; and the &lt;ulink linkID="14383" linkType="Company"&gt;Karmanos Cancer Institute&lt;/ulink&gt; [&lt;ulink linkID="397188" linkType="reference"&gt;397188&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-06-01T00:00:00.000Z</StatusDate><Source id="821842" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="201">Liver disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-05-07T00:00:00.000Z</StatusDate><Source id="1657884" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-06-01T00:00:00.000Z</StatusDate><Source id="821842" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-09-23T00:00:00.000Z</StatusDate><Source id="464870" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1034100">Prospect Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-05-13T00:00:00.000Z</StatusDate><Source id="1009210" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3251">End stage renal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-05-07T00:00:00.000Z</StatusDate><Source id="1657884" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-06-01T00:00:00.000Z</StatusDate><Source id="821842" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="2989">Kidney transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-05-07T00:00:00.000Z</StatusDate><Source id="1657884" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-05-07T00:00:00.000Z</StatusDate><Source id="1657884" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-09-23T00:00:00.000Z</StatusDate><Source id="464870" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-09-23T00:00:00.000Z</StatusDate><Source id="464870" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-06-01T00:00:00.000Z</StatusDate><Source id="821842" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-06-01T00:00:00.000Z</StatusDate><Source id="821842" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-05-07T00:00:00.000Z</StatusDate><Source id="1657884" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1034100">Prospect Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-05-13T00:00:00.000Z</StatusDate><Source id="1009210" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1067663">Solana Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-01-20T00:00:00.000Z</StatusDate><Source id="1256452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-01-14T14:37:30.000Z</StatusDate><Source id="229641" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3251">End stage renal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-18T00:00:00.000Z</StatusDate><Source id="1280342" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3251">End stage renal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-30T00:00:00.000Z</StatusDate><Source id="1415877" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-07-06T00:00:00.000Z</StatusDate><Source id="1306570" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-18T00:00:00.000Z</StatusDate><Source id="1280342" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-01-20T00:00:00.000Z</StatusDate><Source id="1256452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17748">La Jolla Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="201">Liver disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-12-17T00:00:00.000Z</StatusDate><Source id="1350887" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-06-14T00:00:00.000Z</StatusDate><Source id="412519" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-06-14T00:00:00.000Z</StatusDate><Source id="412519" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-06-14T00:00:00.000Z</StatusDate><Source id="412519" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-06-19T00:00:00.000Z</StatusDate><Source id="369718" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-06-25T00:00:00.000Z</StatusDate><Source id="327859" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-06-25T00:00:00.000Z</StatusDate><Source id="329224" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-01T00:00:00.000Z</StatusDate><Source id="240220" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22525">GlycoGenesys Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-04-05T00:00:00.000Z</StatusDate><Source id="593503" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1034100">Prospect Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-06-01T00:00:00.000Z</StatusDate><Source id="821878" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1034100">Prospect Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-02-28T00:00:00.000Z</StatusDate><Source id="821842" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1034100">Prospect Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-06-04T00:00:00.000Z</StatusDate><Source id="913322" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-02247"><Name>Cell adhesion molecule</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-02328"><Name>Galectin-3</Name><SwissprotNumbers><Swissprot>P08699</Swissprot><Swissprot>P16110</Swissprot><Swissprot>P17931</Swissprot><Swissprot>P38486</Swissprot><Swissprot>P47845</Swissprot><Swissprot>P47953</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1022450">Mitsubishi Chemical Holdings Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1034100">Prospect Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1067663">Solana Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1091305">Perrigo Co plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14383">Barbara Ann Karmanos Cancer Institute</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17748">La Jolla Pharmaceutical Co</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18225">Massachusetts Institute of Technology</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21091">Ludwig Institute for Cancer Research</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22525">GlycoGenesys Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="19">Company - Joint Venture</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="115773" title="Elan and GlycoGenesys to codevelop GBC-590 with formation of SafeScience joint venture "></Deal><Deal id="127104" title="MIT and SafeScience to analyse GBC-590"></Deal><Deal id="137825" title="La Jolla Pharmaceutical to develop and commercialize Solana Therapeutics' GCS-100 worldwide"></Deal><Deal id="137828" title="Ludwig Cancer Institute to conduct the clinical studies for Solana Therapeutics' GCS-100"></Deal><Deal id="143080" title="Stelic Institute and La Jolla Pharmaceutical to evaluate GCS-100 for liver fibrosis"></Deal><Deal id="165794" title="GBC-590 (Galectin 3 receptor) for cancer"></Deal></Deals><PatentFamilies><PatentFamily id="105601" number="WO-2005095463" title="Modified pectins, compositions and methods related thereto"></PatentFamily><PatentFamily id="1258123" number="US-07491708" title="Modified pectin"></PatentFamily><PatentFamily id="1584656" number="WO-03045908" title="Method for controlling angiogenesis in animals"></PatentFamily><PatentFamily id="209317" number="WO-09601640" title="Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin."></PatentFamily><PatentFamily id="246527" number="WO-00045825" title="Delivery system and methods for gene therapy"></PatentFamily><PatentFamily id="3030381" number="WO-2015138438" title="Compositions and methods for treating kidney disorders"></PatentFamily><PatentFamily id="361661" number="WO-2005027951" title="Method for controlling angiogenesis in animals"></PatentFamily><PatentFamily id="434590" number="WO-2004091634" title="Composition and uses of galectin antagonists"></PatentFamily><PatentFamily id="540246" number="WO-09734907" title="Modified pectin material."></PatentFamily><PatentFamily id="547358" number="WO-03000118" title="Method for enhancing the effectiveness of cancer therapies"></PatentFamily><PatentFamily id="865005" number="WO-2006020027" title="Composition and method for treating hyperproliferative diseases"></PatentFamily><PatentFamily id="940073" number="WO-03000195" title="Method and material for treating immune diseases"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Prospect Therapeutics Inc" id="1034100"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="FUJIFILM Holdings Corp" id="1037804"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="La Jolla Pharmaceutical Co" id="17748"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wayne State University" id="20702"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Michigan Cancer Foundation" id="21114"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlycoGenesys Inc" id="22525"></CompanyLink><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Galectin Therapeutics Inc" id="29637"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>